Cargando…

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

ERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively. Our study aims to determine ERBB2 and ERBB3 mutations frequencies in grade 3 and/or ERBB2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deniziaut, Gabrielle, Tille, Jean Christophe, Bidard, François-Clément, Vacher, Sophie, Schnitzler, Anne, Chemlali, Walid, Trémoulet, Laurence, Fuhrmann, Laetitia, Cottu, Paul, Rouzier, Roman, Bièche, Ivan, Vincent-Salomon, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341983/ https://www.ncbi.nlm.nih.gov/pubmed/27602491 http://dx.doi.org/10.18632/oncotarget.11819

Ejemplares similares

Biopathological Significance of PIWI–piRNA Pathway Deregulation in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020)

EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
por: Shen, Wei-Wei, et al.
Publicado: (2020)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer
por: Perrot-Applanat, Martine, et al.
Publicado: (2019)

Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer
por: Alexander, John, et al.
Publicado: (2022)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis
por: Lallemand, François, et al.
Publicado: (2017)

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism
por: Vacher, Sophie, et al.
Publicado: (2018)

Distinct expression profiles and functions of Kindlins in breast cancer
por: Azorin, Paula, et al.
Publicado: (2018)

High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter
por: Drak Alsibai, Kinan, et al.
Publicado: (2019)

Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer
por: Vacher, Sophie, et al.
Publicado: (2020)

Impact de l’épidémie de COVID-19 sur les demandes de prise en charge initiale pour cancer du sein
por: Héquet, Delphine, et al.
Publicado: (2020)

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study
por: Callens, Céline, et al.
Publicado: (2021)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

The Expression of the Zonula Adhaerens Protein PLEKHA7 Is Strongly Decreased in High Grade Ductal and Lobular Breast Carcinomas
por: Tille, Jean-Christophe, et al.
Publicado: (2015)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways
por: Laé, Marick, et al.
Publicado: (2016)

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2019)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
por: Darrigues, Lauren, et al.
Publicado: (2021)

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
por: Cizkova, Magdalena, et al.
Publicado: (2012)

Pleomorphic lobular carcinoma: is it more similar to a classic lobular cancer or to a high-grade ductal cancer?
por: Costarelli, Leopoldo, et al.
Publicado: (2017)

Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer
por: Meseure, Didier, et al.
Publicado: (2016)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast
por: Ping, Zheng, et al.
Publicado: (2016)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance
por: Lodillinsky, Catalina, et al.
Publicado: (2021)

Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
por: Christgen, Matthias, et al.
Publicado: (2021)

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification
por: Reyal, Fabien, et al.
Publicado: (2012)

VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX
por: Bonin, Florian, et al.
Publicado: (2018)

ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing
por: Eeckhoutte, Alexandre, et al.
Publicado: (2020)

Incidental parathyroidectomy during total thyroidectomy and functional parathyroid preservation: a retrospective cohort study
por: Melot, Charlotte, et al.
Publicado: (2023)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

Mixed ductal‐lobular carcinomas: evidence for progression from ductal to lobular morphology
por: McCart Reed, Amy E, et al.
Publicado: (2018)

Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial
por: Desportes, Emilie, et al.
Publicado: (2016)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
por: Kurozumi, Sasagu, et al.
Publicado: (2020)

ErbB4 in the brain: Focus on high grade glioma
por: Pitcher, Jamie-Lee, et al.
Publicado: (2022)

Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer
por: Le Goux, Constance, et al.
Publicado: (2020)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
por: Grote, Isabel, et al.
Publicado: (2022)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q8ku5cdheniflhsmq2edevf1cf